Stockreport

Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program

GENEREX BIOTECHNOLOGY  (GNBT) 
US:NASDAQ Investor Relations: generex.com/investor
PDF Initiation of Phase II Clinical Trial to Evaluate the Combination of AE37 + KEYTRUDA® (pembrolizumab) For the Treatment of Patients with Trip [Read more]